Management of high-risk corneal grafts

Doug J. Coster, Keryn Williams

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Corneal transplantation is not invariably successful despite the anterior chamber of the eye being an immunologically privileged site. Inflammation erodes privilege. Other than by reducing inflammation through meticulous surgery, careful postoperative surveillance, and effective topical corticosteroids in the postoperative phase, there is little that a surgeon can do to improve the outlook for the majority of patients receiving corneal transplants. For patients at appreciable risk, HLA Class I matching may help where it is available. So too will systemic immunosuppression where it can be justified. Despite these measures, the results of corneal transplantation have not shown the improvement seen in solid organ transplantation over the last 30 years. New approaches applicable to corneal transplantation are required.

LanguageEnglish
Pages996-1002
Number of pages7
JournalEye
Volume17
Issue number8
DOIs
Publication statusPublished - 1 Jan 2003

Keywords

  • Antibody engineering
  • Gene therapy
  • HLA matching
  • High-risk corneal transplantation
  • Immunosuppression

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems

Cite this

Coster, Doug J. ; Williams, Keryn. / Management of high-risk corneal grafts. In: Eye. 2003 ; Vol. 17, No. 8. pp. 996-1002.
@article{923d7e9040664513b8002f95b4189e86,
title = "Management of high-risk corneal grafts",
abstract = "Corneal transplantation is not invariably successful despite the anterior chamber of the eye being an immunologically privileged site. Inflammation erodes privilege. Other than by reducing inflammation through meticulous surgery, careful postoperative surveillance, and effective topical corticosteroids in the postoperative phase, there is little that a surgeon can do to improve the outlook for the majority of patients receiving corneal transplants. For patients at appreciable risk, HLA Class I matching may help where it is available. So too will systemic immunosuppression where it can be justified. Despite these measures, the results of corneal transplantation have not shown the improvement seen in solid organ transplantation over the last 30 years. New approaches applicable to corneal transplantation are required.",
keywords = "Antibody engineering, Gene therapy, HLA matching, High-risk corneal transplantation, Immunosuppression",
author = "Coster, {Doug J.} and Keryn Williams",
year = "2003",
month = "1",
day = "1",
doi = "10.1038/sj.eye.6700634",
language = "English",
volume = "17",
pages = "996--1002",
journal = "Eye (Basingstoke)",
issn = "0950-222X",
publisher = "Nature Publishing Group",
number = "8",

}

Management of high-risk corneal grafts. / Coster, Doug J.; Williams, Keryn.

In: Eye, Vol. 17, No. 8, 01.01.2003, p. 996-1002.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Management of high-risk corneal grafts

AU - Coster, Doug J.

AU - Williams, Keryn

PY - 2003/1/1

Y1 - 2003/1/1

N2 - Corneal transplantation is not invariably successful despite the anterior chamber of the eye being an immunologically privileged site. Inflammation erodes privilege. Other than by reducing inflammation through meticulous surgery, careful postoperative surveillance, and effective topical corticosteroids in the postoperative phase, there is little that a surgeon can do to improve the outlook for the majority of patients receiving corneal transplants. For patients at appreciable risk, HLA Class I matching may help where it is available. So too will systemic immunosuppression where it can be justified. Despite these measures, the results of corneal transplantation have not shown the improvement seen in solid organ transplantation over the last 30 years. New approaches applicable to corneal transplantation are required.

AB - Corneal transplantation is not invariably successful despite the anterior chamber of the eye being an immunologically privileged site. Inflammation erodes privilege. Other than by reducing inflammation through meticulous surgery, careful postoperative surveillance, and effective topical corticosteroids in the postoperative phase, there is little that a surgeon can do to improve the outlook for the majority of patients receiving corneal transplants. For patients at appreciable risk, HLA Class I matching may help where it is available. So too will systemic immunosuppression where it can be justified. Despite these measures, the results of corneal transplantation have not shown the improvement seen in solid organ transplantation over the last 30 years. New approaches applicable to corneal transplantation are required.

KW - Antibody engineering

KW - Gene therapy

KW - HLA matching

KW - High-risk corneal transplantation

KW - Immunosuppression

UR - http://www.scopus.com/inward/record.url?scp=0347588175&partnerID=8YFLogxK

U2 - 10.1038/sj.eye.6700634

DO - 10.1038/sj.eye.6700634

M3 - Article

VL - 17

SP - 996

EP - 1002

JO - Eye (Basingstoke)

T2 - Eye (Basingstoke)

JF - Eye (Basingstoke)

SN - 0950-222X

IS - 8

ER -